Sponsors: DemeRx IB, Inc. (atai Life Sciences); MAC Clinical Research; ERT: Clinical Trial Technology Solutions

Learn More | Enrol

Study DMX-IB 201 is a phase 1/2a clinical trial of ibogaine HCl (DMX-1002) for the treatment of opioid use disorder (OUD) which is underway at the Manchester clinical unit of MAC Clinical Research (MAC) in the UK. The trial consisting of a randomized, double-blind, placebo-controlled proof of concept stage to demonstrate the efficacy, safety and tolerability of the selected dose in opioid-dependent patients who seek medically supervised opioid withdrawal.

In previously published non-controlled studies, ibogaine has demonstrated rapid and sustained efficacy in treating OUD and has the potential to be a disease modifying treatment for this vulnerable patient population seeking to end their intractable cycle of drug dependence.

“By launching the Phase1/2a trial, we look forward to bringing important data from carefully designed, controlled studies to the existing literature on ibogaine, a compound with substantial history,” said Dr. Deborah Mash, CEO and President of DemeRx. “We are hopeful that this early trial can begin to establish a safe and efficacious profile for Ibogaine, so that we can potentially offer a new option for patients seeking to break free from OUD who have far too few options.”

Dosing of the oral formulation of ibogaine began on 21st September 2021 & is expected to continue until early 2022.

Learn More | Enrol

Information retrieved from clinicaltrials.gov & atai Life Sciences

Support Uthymia

Now more than ever, we need reliable and honest contemporary knowledge of psychedelics to be globally accessible. We rely on your support to keep us going; support the dissemination of everything psychedelic with a one-time or recurring contribution and become a Uthymia community member today!